 | • レポートコード：QYR2104Z3018 • 出版社/出版日：QYResearch / 2021年4月15日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、特発性肺線維症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤）、用途別市場規模（病院、診療所、外来手術センター、学術・研究機関）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・特発性肺線維症の市場動向 ・企業の競争状況、市場シェア ・特発性肺線維症の種類別市場規模（全身性コルチコステロイド、免疫抑制薬、チロシンキナーゼ阻害剤、抗線維化剤） ・特発性肺線維症の用途別市場規模（病院、診療所、外来手術センター、学術・研究機関） ・特発性肺線維症の北米市場規模2016-2027（アメリカ、カナダ） ・特発性肺線維症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・特発性肺線維症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・特発性肺線維症の中南米市場規模2016-2027（メキシコ、ブラジル） ・特発性肺線維症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（MediciNova、Boehringer Ingelheim、F. Hoffmann-La Roche、FibroGen、Promedior、Merck、Galapagos、Prometic Life Sciences、Cipla） ・結論 |
Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.
An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.
Market Analysis and Insights: Global Idiopathic Pulmonary Fibrosis Market
The global Idiopathic Pulmonary Fibrosis market size is projected to reach US$ 3080.7 million by 2026, from US$ 1618.8 million in 2019, at a CAGR of 9.5% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Idiopathic Pulmonary Fibrosis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Idiopathic Pulmonary Fibrosis market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Idiopathic Pulmonary Fibrosis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Idiopathic Pulmonary Fibrosis market.
Global Idiopathic Pulmonary Fibrosis Scope and Market Size
Idiopathic Pulmonary Fibrosis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Pulmonary Fibrosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Systemic Corticosteroids
Immunosuppressant Drugs
Tyrosine Kinase Inhibitors
Antifibrotic Agents
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
MediciNova
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen
Promedior
Merck
Galapagos
Prometic Life Sciences
Cipla
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Systemic Corticosteroids
1.2.3 Immunosuppressant Drugs
1.2.4 Tyrosine Kinase Inhibitors
1.2.5 Antifibrotic Agents
1.3 Market by Application
1.3.1 Global Idiopathic Pulmonary Fibrosis Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Academic and Research Organizations
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Idiopathic Pulmonary Fibrosis Market Perspective (2016-2027)
2.2 Idiopathic Pulmonary Fibrosis Growth Trends by Regions
2.2.1 Idiopathic Pulmonary Fibrosis Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Idiopathic Pulmonary Fibrosis Historic Market Share by Regions (2016-2021)
2.2.3 Idiopathic Pulmonary Fibrosis Forecasted Market Size by Regions (2022-2027)
2.3 Idiopathic Pulmonary Fibrosis Industry Dynamic
2.3.1 Idiopathic Pulmonary Fibrosis Market Trends
2.3.2 Idiopathic Pulmonary Fibrosis Market Drivers
2.3.3 Idiopathic Pulmonary Fibrosis Market Challenges
2.3.4 Idiopathic Pulmonary Fibrosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Pulmonary Fibrosis Players by Revenue
3.1.1 Global Top Idiopathic Pulmonary Fibrosis Players by Revenue (2016-2021)
3.1.2 Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Players (2016-2021)
3.2 Global Idiopathic Pulmonary Fibrosis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Idiopathic Pulmonary Fibrosis Revenue
3.4 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio
3.4.1 Global Idiopathic Pulmonary Fibrosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Idiopathic Pulmonary Fibrosis Revenue in 2020
3.5 Idiopathic Pulmonary Fibrosis Key Players Head office and Area Served
3.6 Key Players Idiopathic Pulmonary Fibrosis Product Solution and Service
3.7 Date of Enter into Idiopathic Pulmonary Fibrosis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Idiopathic Pulmonary Fibrosis Breakdown Data by Type
4.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Type (2016-2021)
4.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2022-2027)
5 Idiopathic Pulmonary Fibrosis Breakdown Data by Application
5.1 Global Idiopathic Pulmonary Fibrosis Historic Market Size by Application (2016-2021)
5.2 Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Idiopathic Pulmonary Fibrosis Market Size (2016-2027)
6.2 North America Idiopathic Pulmonary Fibrosis Market Size by Type
6.2.1 North America Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021)
6.2.2 North America Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027)
6.2.3 North America Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2027)
6.3 North America Idiopathic Pulmonary Fibrosis Market Size by Application
6.3.1 North America Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021)
6.3.2 North America Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027)
6.3.3 North America Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2027)
6.4 North America Idiopathic Pulmonary Fibrosis Market Size by Country
6.4.1 North America Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021)
6.4.2 North America Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Idiopathic Pulmonary Fibrosis Market Size (2016-2027)
7.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Type
7.2.1 Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021)
7.2.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027)
7.2.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2027)
7.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Application
7.3.1 Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021)
7.3.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027)
7.3.3 Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2027)
7.4 Europe Idiopathic Pulmonary Fibrosis Market Size by Country
7.4.1 Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021)
7.4.2 Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size (2016-2027)
8.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Type
8.2.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2027)
8.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Application
8.3.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2027)
8.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region
8.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Idiopathic Pulmonary Fibrosis Market Size (2016-2027)
9.2 Latin America Idiopathic Pulmonary Fibrosis Market Size by Type
9.2.1 Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021)
9.2.2 Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027)
9.2.3 Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2027)
9.3 Latin America Idiopathic Pulmonary Fibrosis Market Size by Application
9.3.1 Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021)
9.3.2 Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027)
9.3.3 Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2027)
9.4 Latin America Idiopathic Pulmonary Fibrosis Market Size by Country
9.4.1 Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021)
9.4.2 Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size (2016-2027)
10.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Type
10.2.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2027)
10.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Application
10.3.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2027)
10.4 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country
10.4.1 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 MediciNova
11.1.1 MediciNova Company Details
11.1.2 MediciNova Business Overview
11.1.3 MediciNova Idiopathic Pulmonary Fibrosis Introduction
11.1.4 MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.1.5 MediciNova Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Details
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Introduction
11.2.4 Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.2.5 Boehringer Ingelheim Recent Development
11.3 F. Hoffmann-La Roche
11.3.1 F. Hoffmann-La Roche Company Details
11.3.2 F. Hoffmann-La Roche Business Overview
11.3.3 F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Introduction
11.3.4 F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.3.5 F. Hoffmann-La Roche Recent Development
11.4 FibroGen
11.4.1 FibroGen Company Details
11.4.2 FibroGen Business Overview
11.4.3 FibroGen Idiopathic Pulmonary Fibrosis Introduction
11.4.4 FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.4.5 FibroGen Recent Development
11.5 Promedior
11.5.1 Promedior Company Details
11.5.2 Promedior Business Overview
11.5.3 Promedior Idiopathic Pulmonary Fibrosis Introduction
11.5.4 Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.5.5 Promedior Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Idiopathic Pulmonary Fibrosis Introduction
11.6.4 Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.6.5 Merck Recent Development
11.7 Galapagos
11.7.1 Galapagos Company Details
11.7.2 Galapagos Business Overview
11.7.3 Galapagos Idiopathic Pulmonary Fibrosis Introduction
11.7.4 Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.7.5 Galapagos Recent Development
11.8 Prometic Life Sciences
11.8.1 Prometic Life Sciences Company Details
11.8.2 Prometic Life Sciences Business Overview
11.8.3 Prometic Life Sciences Idiopathic Pulmonary Fibrosis Introduction
11.8.4 Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.8.5 Prometic Life Sciences Recent Development
11.9 Cipla
11.9.1 Cipla Company Details
11.9.2 Cipla Business Overview
11.9.3 Cipla Idiopathic Pulmonary Fibrosis Introduction
11.9.4 Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021)
11.9.5 Cipla Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Idiopathic Pulmonary Fibrosis Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Systemic Corticosteroids
Table 3. Key Players of Immunosuppressant Drugs
Table 4. Key Players of Tyrosine Kinase Inhibitors
Table 5. Key Players of Antifibrotic Agents
Table 6. Global Idiopathic Pulmonary Fibrosis Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Idiopathic Pulmonary Fibrosis Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Idiopathic Pulmonary Fibrosis Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Idiopathic Pulmonary Fibrosis Market Share by Regions (2016-2021)
Table 10. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Idiopathic Pulmonary Fibrosis Market Share by Regions (2022-2027)
Table 12. Idiopathic Pulmonary Fibrosis Market Trends
Table 13. Idiopathic Pulmonary Fibrosis Market Drivers
Table 14. Idiopathic Pulmonary Fibrosis Market Challenges
Table 15. Idiopathic Pulmonary Fibrosis Market Restraints
Table 16. Global Idiopathic Pulmonary Fibrosis Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Idiopathic Pulmonary Fibrosis Market Share by Players (2016-2021)
Table 18. Global Top Idiopathic Pulmonary Fibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2020)
Table 19. Ranking of Global Top Idiopathic Pulmonary Fibrosis Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Idiopathic Pulmonary Fibrosis Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Idiopathic Pulmonary Fibrosis Product Solution and Service
Table 23. Date of Enter into Idiopathic Pulmonary Fibrosis Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2016-2021)
Table 27. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Idiopathic Pulmonary Fibrosis Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Application (2016-2021)
Table 31. Global Idiopathic Pulmonary Fibrosis Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size by Country (2022-2027) & (US$ Million)
Table 63. MediciNova Company Details
Table 64. MediciNova Business Overview
Table 65. MediciNova Idiopathic Pulmonary Fibrosis Product
Table 66. MediciNova Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 67. MediciNova Recent Development
Table 68. Boehringer Ingelheim Company Details
Table 69. Boehringer Ingelheim Business Overview
Table 70. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Product
Table 71. Boehringer Ingelheim Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 72. Boehringer Ingelheim Recent Development
Table 73. F. Hoffmann-La Roche Company Details
Table 74. F. Hoffmann-La Roche Business Overview
Table 75. F. Hoffmann-La Roche Idiopathic Pulmonary Fibrosis Product
Table 76. F. Hoffmann-La Roche Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 77. F. Hoffmann-La Roche Recent Development
Table 78. FibroGen Company Details
Table 79. FibroGen Business Overview
Table 80. FibroGen Idiopathic Pulmonary Fibrosis Product
Table 81. FibroGen Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 82. FibroGen Recent Development
Table 83. Promedior Company Details
Table 84. Promedior Business Overview
Table 85. Promedior Idiopathic Pulmonary Fibrosis Product
Table 86. Promedior Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 87. Promedior Recent Development
Table 88. Merck Company Details
Table 89. Merck Business Overview
Table 90. Merck Idiopathic Pulmonary Fibrosis Product
Table 91. Merck Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 92. Merck Recent Development
Table 93. Galapagos Company Details
Table 94. Galapagos Business Overview
Table 95. Galapagos Idiopathic Pulmonary Fibrosis Product
Table 96. Galapagos Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 97. Galapagos Recent Development
Table 98. Prometic Life Sciences Company Details
Table 99. Prometic Life Sciences Business Overview
Table 100. Prometic Life Sciences Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 101. Prometic Life Sciences Recent Development
Table 102. Cipla Company Details
Table 103. Cipla Business Overview
Table 104. Cipla Idiopathic Pulmonary Fibrosis Product
Table 105. Cipla Revenue in Idiopathic Pulmonary Fibrosis Business (2016-2021) & (US$ Million)
Table 106. Cipla Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Pulmonary Fibrosis Market Share by Type: 2020 VS 2027
Figure 2. Systemic Corticosteroids Features
Figure 3. Immunosuppressant Drugs Features
Figure 4. Tyrosine Kinase Inhibitors Features
Figure 5. Antifibrotic Agents Features
Figure 6. Global Idiopathic Pulmonary Fibrosis Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Academic and Research Organizations Case Studies
Figure 11. Idiopathic Pulmonary Fibrosis Report Years Considered
Figure 12. Global Idiopathic Pulmonary Fibrosis Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Idiopathic Pulmonary Fibrosis Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Idiopathic Pulmonary Fibrosis Market Share by Regions: 2020 VS 2027
Figure 15. Global Idiopathic Pulmonary Fibrosis Market Share by Regions (2022-2027)
Figure 16. Global Idiopathic Pulmonary Fibrosis Market Share by Players in 2020
Figure 17. Global Top Idiopathic Pulmonary Fibrosis Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Idiopathic Pulmonary Fibrosis Revenue in 2020
Figure 19. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2016-2021)
Figure 20. Global Idiopathic Pulmonary Fibrosis Revenue Market Share by Type (2022-2027)
Figure 21. North America Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Idiopathic Pulmonary Fibrosis Market Share by Type (2016-2027)
Figure 23. North America Idiopathic Pulmonary Fibrosis Market Share by Application (2016-2027)
Figure 24. North America Idiopathic Pulmonary Fibrosis Market Share by Country (2016-2027)
Figure 25. United States Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Idiopathic Pulmonary Fibrosis Market Share by Type (2016-2027)
Figure 29. Europe Idiopathic Pulmonary Fibrosis Market Share by Application (2016-2027)
Figure 30. Europe Idiopathic Pulmonary Fibrosis Market Share by Country (2016-2027)
Figure 31. Germany Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Share by Region (2016-2027)
Figure 41. China Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Idiopathic Pulmonary Fibrosis Market Share by Type (2016-2027)
Figure 49. Latin America Idiopathic Pulmonary Fibrosis Market Share by Application (2016-2027)
Figure 50. Latin America Idiopathic Pulmonary Fibrosis Market Share by Country (2016-2027)
Figure 51. Mexico Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Idiopathic Pulmonary Fibrosis Market Share by Country (2016-2027)
Figure 57. Turkey Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Idiopathic Pulmonary Fibrosis Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. MediciNova Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 61. Boehringer Ingelheim Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 62. F. Hoffmann-La Roche Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 63. FibroGen Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 64. Promedior Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 65. Merck Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 66. Galapagos Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 67. Prometic Life Sciences Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 68. Cipla Revenue Growth Rate in Idiopathic Pulmonary Fibrosis Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed